Inivata’s Liquid Biopsy for Early Use in Breast Cancer Treatment Shows Positive Results

Inivata has reported data from two studies that show the potential of its investigational RaDaR liquid biopsy to detect residual disease following initial treatment as well as early detection of relapse of breast cancer.

RaDaR is a personalized assay that tracks a set of up to 48 tumor-specific variants. In one study, the test was able to detect circulating tumor DNA in 55.2 percent of patients versus just 5.2 percent when using digital polymerase chain reaction to quantify the DNA.

In a second study, RaDaR detected circulating tumor DNA in 88 percent of patients prior to their receiving neoadjuvant therapy.

The results will be presented at the 45th Annual San Antonio Breast Cancer Symposium, Dec. 6-10. The investigational assay received Breakthrough Device designation in 2021.